TERN News and Press, Terns Pharmaceuticals Inc. From 10/03/25

2025-10-03 13:47:03 ET Thesis Structure Therapeutics Inc. (GPCR) is a clinical-stage biotechnology company focused on obesity linked drug developments. It is a GLP-1 oral pure play trying to access one of today’s largest and fastest-growing segments in the pharma industry...

2025-09-30 06:52:21 ET Thesis Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that develops small-molecule product candidates with a focus on oncology and obesity.... Read the full article on Seeking Alpha For further details see: Terns Pharmaceut...

2025-09-18 10:41:29 ET More on 89bio, Novo Nordisk, etc. It Is Time To Buy Novo Nordisk Hand Over Fist Novo Nordisk A/S (NVO) R&D Investor Event Call (Transcript) Novo Nordisk A/S (NVO) Special Call - Slideshow Novo Nordisk pops after Ozempic beats Lilly&...

2025-09-13 16:18:46 ET More on Eli Lilly, Novo Nordisk, etc. The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter Novo Nordisk: GLP-1's Concerns Are Overblown Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 202...

2025-09-13 06:30:00 ET Behind the Latest Moves As of writing this analysis (2 Sep), I notice on the screen that in pre-market trading, Novo Nordisk’s ( NVO ) stock is up 1.5%, while Eli Lilly’s ( LLY ) is similarly down 1.5%. While this has become fairly co...

2025-09-10 12:13:58 ET Terns Pharmaceuticals, Inc. (TERN) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT... Read the full article on Seeking Alpha For further details see: Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley ...

2025-09-03 23:33:38 ET Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript Company Participants Amy Burroughs - CEO & Director Emil Kuriakose - Chief Medical Officer Scott Harris - Chief Development Officer ... Read the full a...

2025-08-05 17:27:39 ET More on Terns Pharmaceuticals Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts Seeking Alpha’s Quant Rating on Terns Pharmaceuticals Historical earnings data for Terns Pharmaceuticals Financial informati...

Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data including 6-month major molecular response (MMR) rates expected in 4Q25 Phase 2 trial of TERN-601 for obesity completed enrollment; 12-week efficacy, safety and tolerability data expected ...

FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...